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THE ASSOCIATION BETWEEN PHYTOESTROGEN INTAKE AND BREAST 
CANCER IN POSTMENOPAUSAL WOMEN 
NJIDEKA ADICHIE 
ABSTRACT 
Breast cancer is the second leading cause of death in women in the U.S. The CDC 
estimates that between 2010 and 2020, there will be an increase in breast cancer in 
women in the United States by 21%, or greater 900,000 new cases per year. (CDC) 
Women are at increased risk for breast cancer due to the fact that some breast cancers 
have cells which are responsive to the hormone estrogen. Further, the risk of developing 
cancer increases as women age. Women who experience menopause after age 55 have an 
increased risk of developing breast cancer. (Surakasula et al., 2014)  
Phytoestrogens, which include isoflavones, are compounds found in plants and 
processed foods, which structurally and functionally mimic the hormone estrogen. Soy is 
frequently found in processed foods regularly consumed in the average American diet 
and is a source of isoflavones, including genistein, daidzein, and daidzein’s metabolite, 
equol. Phytoestrogens can bind to the estrogen receptor and change the expression of 
genes that respond to estrogen, such as the oncogene c-Fos, a protein in breast cancer 
cells which can suppress breast cancer cell growth when it is mutated (Lu et al., 2005). 
Phytoestrogens have been shown to reduce the severity and frequency of some of the 
symptoms of menopause, including a reduction in hot flashes and other estrogen 





been used therapeutically in menopausal women, as they can compensate for lower levels 
of estrogen in the body. There is, however, limited research regarding the consumption of 
soy and increased risk for cancer in postmenopausal women. 
 The objective of this study was to determine whether increasing levels of urinary 
phytoestrogens are correlated with a decreased risk of breast cancer in postmenopausal 
women. The analysis observes 2,439 postmenopausal female subjects equal to or greater 
than 45 years of age who had urinary phytoestrogen and reproductive health data in the 
1999-2010 National Health and Nutrition Examination Survey database. The dietary data 
was obtained from the U.S. Department of Agriculture’s Agricultural Research Service 
database. 
 Logistic regression models constructed using SAS were used to assess the change 
in the relative risk for cancer across low, medium, and high levels of urinary daidzein, 
genistein, and equol. Variables of interest, including demographic, body measures, 
dietary patterns, and lab measures, were compared to a base model, which adjusts for age 
only. 
It was found that the relative risk for breast cancer in postmenopausal women was 
not significantly different in the tertiles and quintiles of urinary phytoestrogens. The 
greatest increase in the likelihood of breast cancer in postmenopausal women was found 
to be 1.81 times in the third tertile of daidzein, increasing the risk by 81%. There was no 
significant protective effect of increasing levels of urinary phytoestrogens against breast 
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Breast Cancer: The Disease and Its Mechanism of Action 
  
Breast cancers are tumors of the epithelium and develop from cells that line the 
ducts and lobules. (Kosir, 2019) It is most likely that women will develop breast cancer 
after age 55. (Surakasula et al., 2014) Breast cancer presents as ductal carcinoma or 
lobular carcinoma. Ductal carcinomas are detected by mammography, while lobular 
carcinomas are not detected by the same means (lobular carcinomas are detected via 
breast-specific gamma imaging, which has a sensitivity of 93%, as found by Brem et al., 
2009). Breast cancer invades the lymph nodes to spread. Some breast cancers have 
estrogen and progesterone receptors, which when bound by estrogen (or estrogenic 
compounds such as isoflavones), lead to DNA replication and cell division.  
There are estrogen-receptor positive breast cancers and estrogen receptor negative 
breast cancers, the former of which is influenced by estrogen (and estrogenic compounds 
like phytoestrogens). Breast cancer not only expresses receptors for hormones, it can also 
be classified as triple negative, meaning it does not express receptors for estrogen, 
progesterone, or human epidermal growth factor receptor 2 (HER2). (National Cancer 
Institute)  
Cancer is influenced by a few different exposures, including alcohol and 
cigarettes, the latter of which contains nicotine and its metabolite, cotinine. Tobacco 
contains carcinogenic and mutagenic chemicals, N-nitrosamines, aromatic amines, 1,3-
butadiene, benzene, aldehydes, and ethylene oxide, to name a few. (CDC, 2010) Ethanol 
is a biphasic drug, which is toxic when consumed in large amounts. Cytochromes are 
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enzymes which metabolize alcohol and the chemicals found in cigarettes. Alcohol 
metabolism, via CYP2E1, leads to free radical formation (1-hydroxyethyl radical). 
(Leung et al., 2013) The response to free radical formation is inflammation.  
The cancer microenvironment is inflammatory, as inflammatory cells infiltrate 
areas of tumorigenesis. Pro-inflammatory activating signals include tumor-associated 
macrophages, dendritic cells, and reactive oxygen species. “Elevated ROS levels, 
accompanied with down-regulation of cellular antioxidant enzyme systems, result in 
malignant transformation via different molecular targets, such as NF-κB and nuclear 
factor (erythroid-derived 2)-like-2 factor (Nrf2). Signaling cascades regulated by these 
key factors generate an inflammatory environment leading to the suppression of apoptotic 
cell death, tumor proliferation, angiogenesis, and metastasis; which cumulatively 
augment initiation, development, and progression of malignant neoplasms.” (Aggarwal, 
2019) Reactive oxygen species and alteration in redox balance leads to DNA damage, an 
instigator of cancer initiation and cancer progression. 
 
Estrogen Receptors, Estrogen, and Their Role in Breast Cancer Mechanisms 
 Estrogen receptors are nuclear hormone receptors (NHRs), which act as 
transcription factors. (Yaşar et al, 2017) There are two types of estrogen receptors, 
estrogen receptor alpha (ER) and estrogen receptor beta (ER), either of which is 
capable of being overexpressed in breast cancer. The ligands for these receptors are 
steroid hormones, in this case, estrogens, which interact with these receptors by diffusion 
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through the plasma membrane. Estrogenic compounds also act as ligands for these 
receptors, as structural similarity permits binding.  
Estrogen is known in three forms, estrone (E1), estradiol (E2), and estriol (E3). 
Estradiol, also called 17b-estradiol, is the most potent form of estrogen. Estrogen controls 
the growth of the uterine lining, regulation of the menstrual cycle, promotes osteoblast 
activity, and produces female secondary sex characteristics such as widening of the hips, 
growth of breasts, and pubic and armpit hair. 17-estradiol’s structure is a four-
membered ring with two hydroxyl groups and a methyl group, synthesized from 
cholesterol (Figure 1). Cholesterol is converted to pregnenolone by the enzyme 20,22-
desmolase. There are two pathways that this steroid intermediate can take to become an 
estrogen. Pregnenolone is converted to 17--hydroxypregnenolone by 17--hydroxylase. 
17--hydroxypregnenolone is then converted to DHEA by the same enzyme. Then 3--
hydroxy steroid dehydrogenase converts the DHEA to androstenedione. Androstenedione 
becomes testosterone by way of 17--hydroxy dehydrogenase. Aromatase then converts 
testosterone to estradiol. Androstenedione can also become estrone via aromatase. 
Alternatively, pregnenolone can become progesterone, then convert to 17--
hydroxyprogesterone, androstenedione, and then an estrogen by way of the enzymes 3--
hydroxy steroid dehydrogenase, 17--hydroxylase (this same enzyme employed twice), 
17--hydroxy dehydrogenase, and aromatase. Estrogen is synthesized in the theca cells in 






Figure 1. 17-estradiol 
Estrogen is capable of interacting with receptors other than its own. This is 
important when considering its mechanism of action in cancer. The hormone can interact 
with the seven transmembrane G protein coupled receptor, GPR30, which is considered a 
novel estrogen receptor in the cell membrane of target cells (Molina et al., 2018). There is 
GPR30-mediated transactivation of epidermal growth factor receptors (EGFR) in breast 
cancer (Figure 2). (Fujiwara et al., 2012) Estrogen can also transactivate the epidermal 
growth factor receptor (EGFR), and as a result play a role in signaling in the mitogen-
activated protein kinase pathway (MAPK) (Filardo, 2000). The kinases in the MAPK 
family (RAS, RAF, ERK) are altered in cancers, the end product of which is alteration in 
the transcription of genes vital in the cell cycle. This is the rationale behind MAPK 
inhibitors as treatment for cancer (Braicu et al., 2019).  
5 
The Role of Cadmium and Nickel in Estrogen Receptor Signaling and Breast Cancer: Metalloestrogens or Not? 
Figure 2. Crosstalk between GPR30, EGFR, ER, ER, and MAPK Estrogen 
pathways initiate the transcription of genes that are needed for cell growth and development. When 
estrogen acts via EGFR/GPR30, the transcription is rapidly-acting, while the activation through ER and 
ER is long-term. When estrogen acts on its receptors, direct transcription activation in the nucleus occurs. 
This same effect is exhibited through mitogen-activated protein kinases. Response elements are sequences 
of DNA that are located in the promoter regions of genes. Response elements bind to hormone-receptor 
complexes to regulate transcription. ERE = estrogen response element, SRE = serum response element, 
CRE = cAMP response element.  
In treatment of ER+ breast cancer, estradiol can be administered in high doses in 
order to reduce tumor size and lead to sustained partial remission. The reason that 
treatment with high-dose estradiol exerts anticancer effects is due to its downstream 
activation of caspases, which induce apoptosis (Kota et al., 2017). This form of treatment 
targets the alpha estrogen receptor. Mitochondrial-mediated apoptosis is the result of high 
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estrogen increasing the content of a pro-apoptotic B-cell called Bcl2-associated X 
protein. 
Interestingly, another form of treatment for breast cancer involves inhibiting 
estradiol. This occurs through the inhibition of the enzyme aromatase, which converts 
between androstenedione and testosterone prior to the production of estradiol. It would 
initially appear to be counterintuitive that one treatment for ER+ breast cancer focuses on 
blocking the production of estradiol while another treatment is instead the hormone itself. 
As previously mentioned, some breast cancers overexpress the beta estrogen receptor, 
which has been found to lead to slower growth of tumors in the presence of estradiol. 
(National Cancer Institute) The influence of ligands on breast cancer are further 
explained by receptors tyrosine kinases. 
Receptors tyrosine kinases (RTKs) initiate another pathway that leads to cellular 
proliferation. Receptors tyrosine kinases are activated by ligands. These ligands include 
epidermal growth factors (EGFs), platelet-derived growth factors (PDGFs), and insulin-
like growth factors (IGFs). These factors are relevant in terms of breast cancer. EGFs 
cause proliferation of epidermal cells, which are located in many organs, including the 
uterus, cervix, ovarian, and breast tissues. It has also been found that insulin-like growth 
factors and estrogens interact in breast carcinomas to activate pathways that cause 
cellular proliferation (Hamelers and Steenbergh, 2003). 
The RTK pathway is relevant in the mechanism of cancer because the end-
products include inflammatory cytokines (markers of cancer such as interleukins and 
tumor necrosis factor), cellular proliferation, and cellular differentiation. In the RTK 
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pathway, EGF binds to one receptor subunit in the cell’s plasma membrane and causes 
conformational changes. The conformational changes initiate a second receptor in the 
plasma membrane to come closer to the first receptor. The two receptor subunits then 
form a dimer. This results in phosphorylation events on tyrosine residues within the cell. 
Each phosphorylated tyrosine causes an individual response. One of these responses is to 
the GTPase known as RAS (Figure 3). RAS takes a GTP molecule and hydrolyzes it to 
GDP and Pi. Subsequently, a GTPase activating protein binds to RAS to increase GTP 
hydrolysis. When RAS cleaves GTP to GDP and Pi, the GDP stays bound to RAS. An 
exchange factor then exchanges bound GDP for GTP to return RAS to its active 
conformation. GTP bound Ras can interact with RAF (a serine-threonine protein kinase). 
RAF phosphorylates the protein kinase MEK. MEK then phosphorylates the protein 
kinase ERK. ERK is activated and translocates to the cell nucleus to phosphorylate 
transcription factors that are required for cell division. (Krakstad & Chekenya, 2010) This 
is how growth factors increase cell proliferation rate. 
Another phosphorylation cascade activated by the dimerization of EGF receptors 
stems from the adaptor protein GRB (Figure 3). This cascade depicts the activation of 
AKT, which has specific effects on cancer via Mdm2, IKKs, mTOR, caspases, and BAD. 
These proteins affect cellular proliferation, apoptosis, and the release of inflammatory 
cytokines. When EGF binds to the EGF receptor, GRB binds to one phosphorylated 
tyrosine in the dimerized epidermal growth factor receptor molecule. PTEN binds RAS, 
which activates PI3K. Active PI3K converts PIP2 to PIP3. PIP3 activates PDK1, an 
activator of the kinase AKT. AKT produces multiple important responses. In particular, 
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AKT phosphorylates the anti-apoptotic protein Bcl-2 antagonist of cell death (BAD), 
which is conducive to cancer proliferation when apoptosis cannot occur in irregular cell 
growth. (Warr & Shore, 2008) Like epidermal growth factors and estrogen, 
phytoestrogens influence breast cancers by acting via receptors which cross-communicate 
and are linked to these second messenger signaling cascades. 
 
Survival signalling [sic] and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. 
 
Figure 3. Receptor Tyrosine Kinase Pathway There are kinases in the RTK pathway which are 
hyperactive. Kinases include, AKT (also known as protein kinase B), MEK, ERK, PI3K, IB, mTOR, and 
phosphoinositide-dependent kinase 1 (PDK1). These hyperactive kinases mediate the growth and 
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angiogenesis of cancer cells. AKT activation produces factors which help those cells survive (NF-B, IB) 
and also inhibits apoptosis of those cells (BAD). 
Human epidermal growth factor receptors (HERs) are often mutated in cancers. 
The dimerization of receptors on the plasma membrane of the cell is necessary to begin 
the chain of events via phosphorylation. Human epidermal growth factor receptors 
(EGFRs) can also heterodimerize. They can then bind to different epidermal growth 
factor isoforms with different specificities. This creates signaling mosaics. The family of 
all these epidermal growth factors, human epidermal growth factor receptor 2 (HER2), is 
constitutively active; it doesn’t require ligand to be activated. It can spontaneously 
dimerize. Mutations in HER 2 have been described in cancers, particularly in breast 
cancer. About 25% of all patients have gene amplification of HER2. This increases basal 
HER2 signaling. This increases cell growth and proliferation, leading to metastatic breast 
cancer. 
Activation of steroid hormone receptors can have a myriad of effects and include 
upregulation of growth factors and receptor tyrosine kinases (Yu, et al., 2010). Due to the 
end effect of cellular proliferation, this pathway is active in certain cancers. Uterine and 
breast cancers are influenced by growth factors, and estrogen acts as one of these in the 
cancer pathway. One of the ligands in the tyrosine kinase pathway includes human 
epidermal growth factor (EGF). Some breast cancers are human epidermal growth factor 
receptor positive (HER). The connection with estrogen lies in the finding that there is 
communication between the estrogen receptor  and receptor tyrosine kinase pathways. 
 
10 
There are various hormone-related receptors in the body. A few of these include 
estrogen-related receptors, progesterone receptors, and other nuclear receptors. Estrogen 
receptors include estrogen receptor  and estrogen receptor . It has been found that 
estrogen is one of the hormones which promotes cell-cycle progression of certain breast 
cancer cells (Tian et al., 2018), indicative of the hormone’s role in being cancer-
promoting. One example is where breast cancers are estrogen-receptor  positive. This 
means that activation of the ER- pathway decreases sensitivity to cancer treatment and 
is activating for cancer.  
 
Phytoestrogen Structure and Type 
 Phytoestrogens are prevalent in plants and in soy, which contains various 
phytochemicals considered to be physiologically beneficial. These phytochemicals 
include isoflavones, saponins, phenolic acids, phytic acid, and sphingolipids. (Wang & 
Wixon, 1999) Included in the isoflavones are genistein, daidzein, and daidzein’s 
metabolite, equol. Instead of being 4-membered with hydroxyl functional units like the 
most potent form of estrogen,17-estradiol, genistein, daidzein, and equol are 3-
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Figure 5. Metabolism of Daidzein to Equol 
 
The Role of Genistein, Daidzein, and Equol in the Mechanism of Cancer 
 Ligands which are structurally similar to estrogen are implicated in the 
mechanism of cancer. “Estrogen is regulated by sulfation and desulfation, meaning it is 
activated and deactivated by this chemical process. Genistein and daidzein are inhibitory 
in the estrogen pathway, where they prevent this sulfation, and therefore activation, from 
occurring.” (Poschner et al., 2017) Previous research on genistein and daidzein found that 
genistein promotes proliferation of ER positive breast cancer cells at low concentration. 
(Poschner, 2017) Though they were found to lead to proliferation at low doses, genistein 
and daidzein were found to inhibit the growth of tumors at high doses. 
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Equol was found to promote breast cancer progression by regulating protein 
synthesis initiation, “equol increases the expression of the eukaryotic protein synthesis 
initiation factor eIF4G1, and the transcription factor c-Myc.” (Cruz-Collazo et al., 2019) 
The initiation factor eIF4G1 was found to lead to the synthesis of pro-cancer molecules 
such as matrix metalloproteinases, which enhance angiogenesis, Cyclin D, the 
overexpression of which is linked to development and progression of cancer, and Bcl-XL, 
a protein which modulates angiogenesis in tumors. C-Myc is an oncogene which helps to 
produce ATP and increase cell mass to trigger DNA replication and cell division, 
conditions which are conducive for cancer. The isoflavones have been found to interact at 
key points in the mechanism of cancer, and their effects appear to be dose-dependent. 
The literature indicates various ways in which isoflavones are beneficial for their 
antioxidant and hormone-mimicking properties. Equol has many pi electrons which it can 
donate to neutralize free radicals as well as displays inhibition of nitric oxide and 
superoxide radical production. (Setchell & Clerici, 2010) Genistein “exerts inhibitory 
effects on lipid peroxidation in vitro by several pro-oxidant agents on model and natural 
membranes," as well as on cultured cells, and also prevents activation of a redox-
sensitive transcription factor that is involved in breast cancer, NF-B. (Mazumder & 
Hongsprabhas, 2016) Genistein has been implicated in reducing the occurrence and 
severity of hot flashes in menopausal women, an effect also found when estrogen is 
prescribed for menopausal symptoms. Genistein has an affinity for the beta estrogen 
receptor, which is also activated by estradiol. Structure similarity of genistein to estradiol 
allows the isoflavone to interact with this receptor.  
 
14 
 Daidzein was shown to interact with lipid bilayers and protect membranes from 
lipid peroxidation, another source of oxidative damage. (Dwiecki et al., 2009) 
 
Estrogen and Menopause in Women 
Women typically go through menopause around the age of fifty-one. Menopause 
is classified as 12 months with no bleeding, and the transition is termed peri-menopause. 
During the phase of menopause, estrogen levels drop as a whole, which is the cause of 
many of the symptoms felt during menopause (hot flashes, night sweats, vaginal dryness, 
etc.). After menopause, estrone is primarily produced, and there are lower circulating 
levels of estradiol and estriol. Estrogen is sometimes prescribed to treat the menopausal 
symptoms of hot flashes and night sweats, in combination with progesterone in order to 
prevent uterine cancer.  
It is well known that the risk of breast cancer increases with age, the CDC finding 
that most breast cancers are diagnosed in women fifty years of age or older. Interestingly, 
“In postmenopausal women, estrogen levels in breast tissue are 10 to 50 times the levels 
in blood, and concentrations of estradiol were higher in malignant tissues than in 
nonmalignant tissues, a finding that probably reflects aromatase activity in breast tissue.” 
(Yager & Davidson, 2006) Despite estrogen levels dropping, they are much higher and 
more active in breast tissue, which speaks to its major role in breast cancer, as estrogen 
can transactivate epidermal growth factor receptors, which signal the MAPK pathway 





NHANES and NHANES Studies 
NHANES, the National Health and Nutrition Examination Survey, is a study 
initiated in 1959. It is conducted by National Center for Health Statistics with the goal of 
assessing the nutrition and health status of adults and children in the United States. The 
study collects demographic, socioeconomic, lab, and dietary data on men, women, and 
children, asking health questions in various surveys. The study uses physical 
examinations and interviews with participants to collect data. This data is used to assess 
disease prevalence and risk factors for various diseases. Diseases included in NHANES 
are anemia, diabetes, cardiovascular disease, kidney disease, and obesity, to name a few. 
 NHANES is representative of the U.S. population, including children, men, and 
women of various ages and races. The survey’s participants visit physicians for medical 
aspects of the survey. Blood samples are collected on adult participants. The participants 
are interviewed in their homes by certified personnel. NHANES travels throughout the 
country with mobile examination centers (trailers) with study teams consisting of a 
physician, medical technicians, and dietary interviewers. Information is collected 
electronically and respondents answer survey questions on touch screens.  
NHANES provides a website with its questionnaire's, datasets, and related 
documentation, where survey years are listed and users can access demographic, dietary, 
examination, laboratory, questionnaire, and limited access data files, as well as 
downloadable versions of these data files. Demographic data files include information on 
race, gender, age, income, education, etc. Dietary data uses dietary interviews such as the 
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24-hour dietary recall. The food variables which are specific to isoflavones are not 
consistently asked across survey periods, thus the USDA’s Food Patterns Equivalents 
Database, which also applies to NHANES, is incorporated in this study. The examination 
data from NHANES includes body measures surveys. The laboratory data examines 
various compounds in the blood, serum, and urine. Questionnaire data asks about 
smoking, diet and nutrition, and medical conditions. Limited access surveys ask about 
alcohol use, STDs, and other diseases. NHANES data files can then be processed in 
statistical software, such as SAS and STATA, the former of which is used in this study to 
analyze the data. 
Some previous studies use the urinary phytoestrogen data from NHANES to 
assess the risk of diseases and risk factors for diseases. Shi et al., 2014 found that 
"isoflavonoids were significantly inversely associated with some cardiometabolic risk 
markers, although no clear patterns emerged. Equol was associated with lower serum 
triglyceride and total cholesterol when comparing the highest quartile to the lowest 
quartile for triglyceride, and 202 vs. 217mg/dL for total cholesterol." Some patterns of 
isoflavone intake imply a dose-dependent effect of isoflavones on certain diseases. 
Cancer produces inflammation, and is therefore an indicator of the disease. 
Inflammatory responses are key factors in recognition of the pathways for tumor growth. 
Inflammation is correlated with the progression and prognosis of cancer. (Sylman et al., 
2018) Inflammation can also be measured by C-reactive protein in the blood. C-reactive 
protein is a liver byproduct that is sent into the blood in response to inflammation. High 
CRP indicates inflammation, infection, and possible cancer. Reger et al., 2017, found that 
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there is an association between C-reactive protein and urinary phytoestrogens. The study 
looked at a few more phytoestrogens of interest, including enterolactone, enterodiol, and 
O-desmethylangolensin. It was found that individuals in the highest quartile of total 
urinary phytoestrogens had significantly lower serum CRP than those in the lowest 
quartile of total urinary phytoestrogens. The implication is that cancer risk is lower. 
 
Studies Examining DNA Methylation and Gene Expression in Cancer 
Previous research suggests that it cannot be definitively concluded that the health 
benefits of phytoestrogens outweighs the risks associated with them. The aim of this 
study was to determine whether increasing levels of urinary phytoestrogens indicates a 
decreased risk for breast cancer in postmenopausal women. As mentioned earlier in this 
paper, estrogenic compounds, such as genistein, can bind and influence estrogen receptor 
, which leads to concentration-dependent increases in proliferation of cancerous cells. 
(Rietjens et al., 2017) This effect was found in the breast cancer cell line T47D-ER. 
However, when the beta estrogen receptor is activated, genistein does not have this 
effect. Thus, the receptors are inversely functional, responding differently to the same 
phytoestrogen. Rietjens et al. examined a murine study which found that genistein 
increases DNA methylation of CpG sites during gestation, leading to decreased risk for 
obesity in offspring. This finding could explain the lower incidence of some cancers in 
Asians when compared to Westerners, as effects to phytoestrogen exposure in utero 




Methylation of DNA changes its function, and regulates gene expression as a 
result. Methylation can also cause mutations in genes. An example of such a gene is 
BRCA1, which gives the instructions for making tumor suppressing proteins. When 
BRCA1 is mutated, such as by methylation, so that tumor suppressing proteins are not 
produced, this promotes cancer. Genistein has been implicated in decreasing the 
methylation of tumor suppressor genes by inhibiting DNA methyltransferase. “This may 
allow silenced tumor suppressor genes to be re-expressed, indicating a potential 
beneficial effect of genistein.” (Rietjens et al., 2017) 
 
Aims of the Present Study 
 I hypothesized that with increasing levels of the phytoestrogens equol, genistein, 
and daidzein, the risk of breast cancer in postmenopausal women decreases. Looking at 
pertinent data collected in NHANES, including surveys indicating cancer as a medical 
condition, measured urinary phytoestrogens, as well as relevant data on women’s health, 
logistic regression models were formulated to determine if increased urinary 










Subject Selection Criteria 
 
 The criteria for selecting the 2,439 subjects for this study involved determining 
who had data available for one or more of the urinary phytoestrogens of interest. In order 
to have a sample size large enough to run logistic regression models and yield results, the 
survey years were selected on the basis for available data on the covariates age, BMI, 
race, fruit and vegetable intake, and serum cotinine. Subjects were excluded if they were 
missing data on waist circumference, dietary data, or serum cotinine. There were no 
missing reports for data on age, BMI, and race. 98 subjects were missing dietary data, 
and 137 were missing cotinine data, leaving 2,439 subjects who had data on at least one 
urinary phytoestrogen. All 2,439 subjects selected for analysis had data for urinary 
genistein and daidzein, with 2,390 of these subjects having data for urinary equol. 
 
Survey Variables and Comparable Data for Variables Inconsistent in NHANES 
Survey questions were sorted into various variables. Some of the variables were 
limited, due to some survey questions not being asked consistently across the years 
selected for this study (1999-2010), some questions were asked non-consecutively over 
the years with the same variable name and a different SAS label, or variable names 
changed across the years while the question that corresponds to a variable name remained 
consistent. In order to solve this discrepancy, comparable variables were identified across 
1999-2010 data and combined to create single variables for the entire survey period 
analyzed. Particularly, dietary information was inconsistently surveyed between 1999-
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2010. The questions on soy-containing and phytoestrogen-rich foods were not 
consistently asked. Thus, dietary data had to be extracted from the U.S. Department of 
Agriculture databases. The dietary data from the USDA is an integration of data from two 
nationwide surveys, Continuing Survey of Food Intakes by Individuals and NHANES. 
 
Covariate Testing for Final Logistic Regression Model Design 
A number of covariates on demographic, socioeconomic, food pattern, 
reproductive health, lab, and racial survey data were originally selected from the 1999-
2010 NHANES survey and lab data. Each covariate was compared individually to a base 
model which adjusted for age only, to see which covariates made a difference of 5% or 
greater on the cancer outcome. The covariates which led to a difference equal to or 
greater than 5% were selected for the final model. The final model included the 
covariates age, race, BMI, fruit and vegetable intake, and serum cotinine.  
A number of demographic and socioeconomic variables were included in 
covariate testing to decide on the final logistic regression model. One of the demographic 
variables explored was education, due to the fact that an individual’s education level 
influences their eating and health-related habits. Previous research has found that there is 
an association between education level and dietary behaviour. (Vogel et al., 2017) Even 
in environments where healthy foods are less accessible, individuals with higher degrees 
will make healthier choices as compared to their lower education level counterparts. 
Education was not found to make a difference of 5% or greater on the cancer outcome 
and was not included in the final model. 
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 Another demographic variable that was analyzed was income. Income is relevant 
in that it influences whether people are eating healthy foods because they can/can’t afford 
to buy fresh fruits and vegetables. Income is an essential covariate, as some subjects who 
are lower income may live in food deserts, preventing them from gaining access to foods 
that contain phytoestrogens. Income was not found to create a difference of 5% or greater 
for the outcome and was not included in the final model. 
 
Rationale for Assessing Menopause Status  
Menopause was accounted for by creating categories of menopause in the age 
range of 40-60 years old: very early menopause, early menopause, and late menopause. 
This way, menopause could be defined without excluding the many subjects who had a 
hysterectomy at some point. Subjects were excluded if they were younger than 45 years 
of age and had a hysterectomy, an indication that there may have been some serious 
underlying illness or other issue. Subjects were included as postmenopausal if they 
answered yes to “Had a hysterectomy” and were also older than 45. Other exclusion 
criteria included male sex. To account for missing data, dummy variables were created 
for each variable.  
 Menopause is classified as no menstrual period for 12 months after the last 
menstrual period. The average age at which this occurs is 51. This biological event is 
relevant here in order to classify subjects as postmenopausal when their cancer was 
diagnosed. A variable was created to account for classifying subjects as premenopausal. 
This variable was termed “premenopausal.” A combination of the reproductive health 
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survey questions was used to classify a subject as premenopausal or postmenopausal. If a 
subject answered “Yes” to the survey question Had regular periods in past 12 months/At 
least 1 period in past 12 months, she was assigned to the premenopausal group, and 
dropped from the sample. Subjects who answered “No” to those same survey questions, 
were classified as postmenopausal, including subjects who answered that they had 
already had menopause/hysterectomy in response to the survey question Reason didn’t 
have period. Subjects who were missing reproductive health information who were less 
than 51 years of age, were classified as pre-menopausal, due to maintaining a cut off of 
the average age of menopause at age 51. 
 These pre- and postmenopausal classifications were then combined with the 
breast cancer and age at diagnosis of cancer variables. Age at diagnosis of cancer, Age at 
last period, and Age range at last menstrual period, were used to exclude individuals who 
were diagnosed with cancer prior to cessation of menstruation, seeing as the focus is on 
postmenopausal cancer. Because many survey questions include the answers, “don’t 
know,” “refused,” and “missing,” some subjects lacked information pertaining to 
questions that decipher whether or not a subject is postmenopausal. The subjects who did 
not have survey information for these reproductive health questions, who were equal to or 







Rationale for Body Measures 
There are a few different body measure variables from NHANES’ Examination 
Data that were selected in the analyses: BMI and waist circumference. Body measures are 
relevant for the outcome of cancer because obesity can induce oncogenic reactive oxygen 
species and activate the oxidative phosphorylation events that are seen in the mechanistic 
pathways of cancer. A healthy BMI for women is considered between 18.5 and 24.9 
kg/m2. Below 18.5 kg/m2 is considered underweight, while 25-29.9 kg/m2 is overweight, 
and a BMI of 30 kg/m2 or higher is considered obese. A waist circumference greater than 
88cm is considered overweight and is correlated with higher cardiometabolic risk. Higher 
weight is a theme in levels of oxidative stress. BMI and waist circumference were 
compared to the base model in the logistic regression analyses to see which covariate 
made the most difference for the cancer outcome. BMI was chosen for the final model. 
BMI was measured by stadiometer in the NHANES Mobile Examination Center, trailer 
1.  
Body measures, as well as the food data, are indicative of oxidative stress. High 
fat consumption leads to increased lipid peroxidation, which, as previously described, 
produces free radicals and the oxidative stress that is mechanistically involved in cancer. 
The same result is found in excessive carbohydrate intake in the diet, as some excess 
carbohydrate is stored as fat. In obesity, both fats and carbohydrates are excessively 
consumed, leading to oxidative stress (Manna & Jain, 2015) The body measures variables 
were tested in the logistic models to see what the relative risk of cancer was when 




Consideration for Other Medical Condition Variables  
 The health covariate diabetes was incorporated in covariate testing, as some 
studies have found an increased risk in breast cancer in Type 2 diabetics. “In 
epidemiological studies, elevated levels of insulin or C-peptide (a biomarker of insulin 
production) predict increased risk for colorectal, postmenopausal breast, pancreatic, 
bladder, and endometrial cancers.” (Collins, 2014) The subjects were classified as having 
prevalent diabetes (the variable PrevalentDM), or treated diabetes (the variable 
TreatedDM). These two variables were created from variables in NHANES’ 
Questionnaire Data, the Diabetes data file. The survey questions used to create these 
variables were: Take diabetic pills to lower blood sugar (DID070/DIQ070), and Doctor 
told you have diabetes (DIQ010). The diabetes variables were not selected for the final 
model, as they did not make a difference of 5% or greater on the outcome of cancer. 
 
Rationale for Adjusting Urinary Phytoestrogens for Urinary Creatinine 
 The function of the kidneys is to filter the blood and remove waste. Kidney 
function is relevant to the urinary phytoestrogen data, as complications with the kidneys 
may impact levels of phytoestrogens in the urine. Urinary levels of phytoestrogens tend 
to be higher than serum levels, (Valentin-Blasini et al., 2003) and subjects with low and 
high levels of urinary phytoestrogens might also have had impaired kidney function. This 
may account partially for the wide distribution observed in urinary phytoestrogens. If the 
kidneys aren’t functioning well, there will be an increase in creatinine accumulation in 
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the blood. Thus, creatinine-adjusted urinary equol, genistein, and daidzein were used in 
final models. Urinary phytoestrogens were collected in Mobile Examination Centers in 5-
mL cryovials. 
 
Method for Obtaining Urinary Phytoestrogens 
The urinary phytoestrogen levels were obtained by high performance liquid 
chromatography-electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS). 
This procedure was able to quantitatively detect daidzein, equol, and genistein. Urine 
samples were processed using a procedure called enzymatic deconjugation of the 
glucuronidated phytoestrogens, and solid phase extraction. The phytoestrogens were 
separated from the urine using reversed phase HPLC, detected by ESI-MS/MS, and 
quantified by isotope dilution. 
Categories of the three phytoestrogens of interest (genistein, daidzein, and equol) 
were created to specify low, medium, and high intake of daidzein, genistein, and equol. 
The categories were organized into tertiles, quartiles, and quintiles. Each tertile, quartile, 
and quintile was placed in a logistic regression model when testing each covariate to 
examine the difference in base change for relative risk of breast cancer, compared to a 
base model which adjusted only for age.  
 
Rationale for Serum Cotinine  
 Smoking is documented as a risk factor for cancer. To account for smoking, 
models were also run adjusting for serum cotinine. Cotinine is a metabolite of nicotine, 
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and has a longer half-life than nicotine itself. This makes it a good marker to measure 
smoking. Blood samples were collected in the Mobile Examination Center trailers. Serum 
cotinine was measured via isotope dilution-high performance liquid chromatography / 
atmospheric pressure chemical ionization tandem mass spectrometry.  
 
Rationale for Inclusion of Dietary Data 
Dietary data was collected to identify level of intake of phytoestrogens from food, 
as well as intake of foods and beverages which increase oxidative stress and influence 
cancer risk. Alcohol is associated with oxidative stress, the metabolism of which leads to 
production of reactive oxygen species, a risk factor for cancer. (Alcohol Alert, 2007) 
Alcohol intake was including in the covariate testing, however was not found to influence 
the outcome of breast cancer by 5% or greater, and was not included in the final model. 
These food variables came from the USDA’s Food Patterns Equivalents Database. The 
USDA’s Food Patterns Equivalents Database converts the foods and beverages in the 
Food and Nutrient Database for Dietary Studies into 37 USDA Food Patterns 
components. The dietary data for NHANES 1999-2004 is from the MyPyramid 
Equivalents Product, and 2005-2010 from the Food Patterns Equivalents Database. 
 
Rationale for Demographic Variables 
 Two common risk factors for breast cancer are being female and increased age. At 
age 40, 1 in 65 women will develop breast cancer. By age 50, the risk increases to 1 in 
42, and 1 in 28 at age 60. (National Cancer Institute) Age and gender variables weed out 
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individuals who are male and those who are younger than 45 in order to identify the 




Starting with a total of 62,160 subjects in NHANES from the years 1999-2010, 
16,543 of those have urinary phytoestrogen data, 8,021 of those subjects are female, and 
2,721 of them are greater than or equal to 45 years of age. 46 subjects were missing waist 
measurement data, 98 subjects were missing dietary data, 137 subjects were missing 
cotinine data, which reduced the sample size down to 2,439 subjects. 





  Descriptive statistics of each of the three exposures is shown below. The average 
age was between 62 and 63 years. The racial breakdown of the sample from greatest to 
least was Non-Hispanic White, followed by Non-Hispanic Black, Mexican American, 
Other Hispanic, and lastly, Other – Including Multiracial. The average BMI ranged from 
28.54 -29.88kg/m2. The average total fruit and vegetable intake was between  2.46and 




Table 1. Characteristics of Subjects According to Tertiles of Urinary Daidzein 
 
 
The first tertile of daidzein included the greatest number of Non-Hispanic Whites, 
followed by Non-Hispanic Blacks, Mexican Americans, Other Hispanic, and Other – 
Including Multiracial (Table 1). The first tertile of daidzein had an average age of 62.25 
Tertile 1 urinary 
daidzein (n = 805)
Tertile 2 urinary 
daidzein (n = 820)
Tertile 3 urinary 
daidzein (n = 814)
Characteristics
Age (mean, SD) (years) 62.25 (11.54) 63.60 (11.66) 62.92 (11.71)
Race (N, %)
Mexican American 159 (19.75) 152 (18.54) 147 (18.06)
Other Hispanic 55 (6.83) 38 (4.63)  46 (5.65)
Non-Hispanic White 400 (49.69) 457 (55.73) 439 (55.73)
Non-Hispanic Black 172 (21.37) 148 (18.05) 143 (17.57)
Other - Including Multiracial 19 (2.36) 25 (3.05) 39 (4.79)
BMI (Kg/m
2
, mean, SD) 29.19 (6.74) 29.53 (6.68) 29.12 (6.70)
Fruit and vegetable intake (cups, mean, SD) 2.53 (1.69) 2.59 (1.54) 2.60 (1.60)
Serum cotinine (ng/mL, mean, SD) 53.07 (124.57) 41.10 (117.26) 43.01 (118.56)
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years, a BMI of 29.19kg/m2, an average fruit and vegetable intake of 2.53 cups per day, 
and the highest serum cotinine of all the tertiles of daidzein (53.07ng/mL). The third 
tertile of genistein included the greatest number of Non-Hispanic Whites, followed by 
Mexican Americans, Non-Hispanic Blacks, Other Hispanic, and Other – Including 
Multiracial (Table 2). The third tertile of genistein had an average age of 63.48 years, a 
BMI of 28.85kg/m2, an average fruit and vegetable intake of 2.54 cups per day, and a 
serum cotinine of 42.96ng/mL. 
 
 
Table 2. Characteristics of Subjects According to Tertiles of Urinary Genistein 
 
  The third tertile of equol had the most Non-Hispanic Whites, followed by 
Mexican Americans, Non-Hispanic Blacks, Other Hispanics, and Other – Including 
Multiracial (Table 3). The average age as 63.69 years, BMI was 28.54kg/m2, average 
Tertile 1 urinary 
genistein (n = 816)
Tertile 2 urinary 
genistein (n = 
819)
Tertile 3 urinary 
genistein (n = 
804)
Characteristics
Age (mean, SD) (years) 62.26 (11.15) 63.06 (12.01) 63.48 (11.75)
Race (N, %)
Mexican American 153 (18.75) 157 (19.17) 148 (18.41)
Other Hispanic 42 (5.15) 53 (6.47) 44 (5.47)
Non-Hispanic White 413 (50.61) 429 (52.38) 454 (56.47)
Non-Hispanic Black 190 (23.28) 157 (19.17) 116 (14.43)
Other - Including Multiracial 18 (2.21) 23 (2.81) 42 (5.22)
BMI (Kg/m
2
, mean, SD) 29.46 (6.83) 29.52 (6.59) 28.85 (6.67)
Fruit and vegetable intake (cups, mean, SD) 2.63 (1.73) 2.55 (1.49) 2.54 (1.60)
Serum cotinine (ng/mL, mean, SD) 50.44 (127.98) 43.63 (116.42) 42.96 (115.81)
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fruit and vegetable intake in this tertile was 2.70 cups a day, and the average serum 
cotinine was the lowest of the tertiles of equol at 37.97 ng/mL. 
 
 
Table 3. Characteristics of Subjects According to Tertiles of Urinary Equol 
 
The most abundant characteristics in the sample were white women between the 
ages of 62 and 63, with a BMI in the overweight range (28.54-29.88kg/m2), a serum 
cotinine in the range consistent with those who are light smokers or are exposed to 
secondhand smoke (11-30ng/mL) (University of Rochester Medical Center), and a fruit 
and vegetable intake of under 3 cups per day. When adjusting for age, race/ethnicity, 
BMI, total fruit and vegetable intake, and serum cotinine, there appeared to be a 
protective effect against the outcome of breast cancer in the second tertile of urinary 
equol when compared to the third tertile of equol (which had higher levels of the 
phytoestrogen in the urine), where the likelihood for the outcome was only 0.89 (0.56, 
1.42) times (Table 4). The likelihood for breast cancer decreased by 11%. There was no 
Tertile 1 urinary 
equol (n = 791)
Tertile 2 urinary 
equol (n = 792)
Tertile 3 urinary 
equol (n = 807)
Characteristics
Age (mean, SD) (years) 61.62 (11.53) 63.08 (11.64) 63.69 (11.57)
Race (N, %)
Mexican American 191 (24.15) 159 (20.08) 101 (12.52)
Other Hispanic 42 (5.31) 50 (6.31) 44 (5.45)
Non-Hispanic White 304 (38.43) 414 (52.27) 548 (67.91)
Non-Hispanic Black 222 (28.07) 138 (17.42) 94 (11.65)
Other - Including Multiracial 32 (4.05) 31 (3.91) 20 (2.48)
BMI (Kg/m
2
) (mean, SD) 29.88 (6.89) 29.39 (6.78) 28.54 (6.40)
Fruit and vegetable intake (cups, mean, SD) 2.46 (1.57) 2.57 (1.59) 2.70 (1.67)
Serum cotinine (ng/mL, mean, SD) 61.19 (144.48) 38.55 (106.91) 37.97 (101.63)
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significant reduction in risk for the outcome in the third tertile of equol. No statistically 
significant difference in breast cancer risk was found according to levels of urinary equol. 
 
 
Table 4. Adjusted Odds Ratios for Risk of Breast Cancer in Postmenopausal 
Women with Increasing Tertiles of Urinary Daidzein, Genistein, and Equol 
 
There were no protective benefits of phytoestrogens against breast cancer in 
postmenopausal women found across tertiles of genistein or daidzein. In fact, the risk 
increased by 53% in the second tertile of daidzein. The risk decreased slightly in the 
highest tertile of daidzein, with a risk of 33%. A similar pattern was observed in the 
tertiles of genistein, where the risk increased from the first tertile of genistein to the 
second, with a slight decrease in the highest tertile. The risk of breast cancer in 
postmenopausal women increased by 22% in the second tertile of genistein, and 
increased only by 19% in the highest tertile of genistein. 
Similar results were found across quintiles of the urinary phytoestrogens. There 
was no significant pattern of beneficial effects across the distributions of each 
Urinary Daidzein (ng/mL) OR
0.00141 - 0.27113 1.00 (Ref)
0.27119 - 1.39756 1.53
1.40000 - 589.47368 1.33
Urinary Genistein (ng/mL) OR
0.00096 - 0.14211 1.00 (Ref)
0.14213 - 0.62963 1.22
0.63036 - 112.45614 1.19
Urinary Equol (ng/mL) OR
0.00007 - 0.04615 1.00 (Ref)
0.04635 - 0.11736 0.89















phytoestrogen. Tables 5–7 display the descriptive statistics across quintiles of daidzein, 




Table 5. Characteristics of Subjects According to Quintiles of Urinary Daidzein  
 
In quintile 3 of daidzein, the racial breakdown had the most Non-Hispanic Whites, 
followed by Non-Hispanic Blacks, Mexican-Americans, Other Hispanics, and lastly, 
Other – Including Multiracial, with an average age of 63.57 years. The average BMI in 
the third quintile was 29.63kg/m2, with an average fruit and vegetable intake of 2.26 cups 
per day, and the lowest serum cotinine of all the quintiles of urinary daidzein, 
38.17ng/mL. 
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phytoestrogen. Tables 5-7 display the descriptive statistics across quintiles of daidzein, 
genistein, and equol, respectively. 
 
Table 5. Characteristi s of Subjects According to Quintiles of Urinary Daidzein 
In quintile 3 of daidzein, the racial breakdown had the most Non-Hispanic Whites, 
followed by Non-Hispanic Bl cks, Mexican-Americans, Other Hispanics, and lastly, 
Other – Including Multiracial, with an aver ge age of 63.57 years. The average BMI in 
the third quintile was 29.63kg/m2, with an aver ge fruit and vegetabl  int ke of 2.26 cups 
per day, an  the lowest serum cotinine f all the quintiles of urinary daidzein, 
38.17ng/mL. 
Quintile 1 urinary
daidzein (n = 483)
Quintile 2 urinary
daidzein (n = 481)
Quintile 3 urinary
daidzein (n = 498)
Quintile 4 urinary
daidzein (n = 495)
Quintile 5 urinary
daidzein (n = 482)
Characteristics
Age (mean, SD) (years) 61.20 (11.25) 63.89 (11.54) 63.57 (11.86) 63.40 (11.56) 62.56 (11.85)
Race (N, %)
Mexican American 100 (20.70) 93 (19.33) 81 (16.27) 100 (20.20) 84 (17.43)
Other Hispanic 34 (7.04) 24 (4.99) 26 (5.22) 23 (4.65) 32 (6.64)
Non-Hispanic White 227 (47.00) 262 (54.47) 275 (55.22) 270 (54.55) 262 (54.36)
Non-Hispanic Black 113 (23.40) 87 (18.09) 98 (19.68) 93 (18.79) 72 (14.94)
Other - Including Multiracial 9 (1.86) 15 (3.12) 18 (3.61) 9 (1.82) 32 (6.64)
BMI (Kg/m2, SD) 29.28 (6.90) 29.24 (6.58) 29.63 (6.72) 29.54 (6.70) 28.68 (6.59)
Fruit and vegetable intake (cups, mean, SD) 2.61 (1.76) 2.49 (1.54) 2.62 (1.58) 2.45 (1.51) 2.68 (1.64 )





Table 6. Characteristics of Subjects According to Quintiles of Urinary Genistein 
 
  Across quintiles of urinary genistein, Non-Hispanic Whites accounted for the 
greatest number of subjects by race in the fifth quintile, followed by Mexican-Americans, 
Non-Hispanic Blacks, Other Hispanics, and Other – Including Multiracial, with an 
average age of 63.66 years. The average BMI in the fifth quintile was 28.35kg/m2, and 
the average fruit and vegetable intake was 2.66 cups per day, and an average serum 






genistein (n = 494)
Quintile 3 urinary
genistein (n = 489)
Quintile 4 urinary
genistein (n = 488)
Quintile 5 urinary
genistein (n = 480)
Characteristics
Age (mean, SD) (years) 61.33 (10.83) 63.57 (11.69) 62.88 (12.10) 63.22 (11.75) 63.66 (11.74)
Race (N, %)
Mexican American 89 (18.24) 90 (18.22) 97 (19.84) 100 (20.49) 82 (17.08)
Other Hispanic 26 (5.33) 26 (5.26) 29 (5.93) 27 (5.53) 31 (6.46)
Non-Hispanic White 235 (48.16) 268 (54.25) 263 (53.78) 256 (52.46) 274 (57.08)
Non-Hispanic Black 128 (26.23) 96 (19.43) 89 (18.20) 86 (17.62) 64 (13.33)
Other - Including Multiracial 10 (2.05) 14 (2.83) 11 (2.25) 19 (3.89) 29 (6.04)
BMI (Kg/m
2
, SD) 29.58 (7.15) 29.52 (6.35) 29.28 (6.54) 29.65 (6.58) 28.35 (6.82)
Fruit and vegetable intake (cups, mean, SD) 2.64 (1.70) 2.60 (1.72) 2.52 (1.45) 2.45 (1.48) 2.66 (1.68)




Table 7. Characteristics of Subjects According to Quintiles of Urinary Equol 
Across quintiles of urinary equol, the fifth quintile had the highest number of 
Non-Hispanic Whites, followed by Mexican-Americans, Non-Hispanic Blacks, Other 
Hispanics, and Other – Including Multiracial, with an average age of 63.64 years, an 
average fruit and vegetable intake of 2.83 cups a day, a BMI of 28.24kg/m2, and the 
lowest serum cotinine of all the quintiles of genistein, at 35.68ng/mL. 
Similar to the tertiles, across the distribution of quintiles the most abundant 
subjects in the sample were white women. The average age was between 60 and 63 years, 
with a BMI between 29.24-29.93kg/m2, a serum cotinine level again within the range of 
those who are light smokers or are exposed to second hand cigarette smoke, and a fruit 
and vegetable intake under 3 cups per day. When adjusting for age, race/ethnicity, BMI, 
total fruit and vegetable intake, and serum cotinine, the highest risk for breast cancer in 
postmenopausal women was found in the third quintile of daidzein, 1.81 (0.94, 3.50) 
times as likely, increasing the risk for the outcome by 81%. There was once again no 
pattern of a beneficial effect throughout the rest of the distribution. The results do not 
Quintile 1 urinary
equol (n = 466)
Quintile 2 urinary
equol (n = 482)
Quintile 3 urinary
equol (n = 477)
Quintile 4 urinary
equol (n = 482)
Quintile 5 urinary
equol (n = 483)
Characteristics
Age (mean, SD) (years) 60.66 (10.99) 63.01 (11.96) 62.82 (11.53) 63.80 (11.94) 63.64 (11.36)
Race (N, %)
Mexican American 108 (23.18) 123 (25.52) 96 (20.13) 61 (12.66) 63 (13.04)
Other Hispanic 24 (5.15) 33 (6.85) 24 (5.03) 24 (4.98) 31 (6.42)
Non-Hispanic White 161 (34.55) 215 (44.61) 251 (52.62) 313 (64.94) 326 (67.49)
Non-Hispanic Black 153 (32.83) 96 (19.92) 81 (16.98) 71 (14.73) 53 (10.97)
Other - Including Multiracial 20 (4.29) 15 (3.11) 25 (5.24) 13 (2.70) 10 (2.07)
BMI (Kg/m
2
, SD) 29.80 (6.70) 29.93 (6.95) 29.29 (6.75) 29.08 (6.73) 28.24 (6.29)
Fruit and vegetable intake (cups, mean, SD) 2.41 (1.54) 2.53 (1.59) 2.61 (1.54) 2.51 (1.56) 2.83 (1.78)
Serum cotinine (ng/mL, mean, SD) 74.58 (159.88) 42.03 (114.72) 36.40 (105.04) 41.42 (106.18) 35.68 (99.27)
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support an association between any of these urinary phytoestrogens and breast cancer risk 




Table 8. Adjusted Odds Ratios for Risk of Breast Cancer in Postmenopausal 
Women with Increasing Quintiles of Urinary Daidzein, Genistein, and Equol 
 
With the lowest quintile serving as the referent group, quintiles 2–5 were 
compared to quintile 1 for the outcome of breast cancer in postmenopausal women. 
Because the confidence intervals were wide, there were no statistically significant results 
found between increased urinary phytoestrogens and a decreased risk of breast cancer in 
postmenopausal women. For daidzein, the highest risk was found in the second quintile, 
an increase of 81%. The highest risk for breast cancer in was found in the second quintile 
 
36 
support an association between any of these urinary phytoestrogens and breast cancer risk 
in this cross-sectional study. 
 
Table 8. Adjusted Odds Ratios for Risk of Breast Cancer in Postmenopausal 
Women with Increasing Quintiles of Urinary Daidzein, Genistein, and Equol 
 
With the lowest quintile serving as the referent group, quintiles 2-5 were 
compared to quintile 1 for the outcome of breast cancer in postmenopausal women. 
Because the confidence intervals were wide, there were no statistically significant results 
found between increased urinary phytoestrogens and a decreased risk of breast cancer in 
postmenopausal women. For daidzein, the highest risk was found in the second quintile, 
an increase of 81%. The highest risk for breast cancer in was found in the second quintile 
Urinary Daidzein (ng/mL) OR
0.0014 - 0.1549 1.00 (Ref)
0.1553 - 0.3667 1.48
0.3692 - 0.9734 1.81
0.9750 - 2.9450 1.67
2.9457 - 589.4737 1.62
Urinary Genistein (ng/mL) OR
0.0010 - 0.0788 1.00 (Ref)
0.0792 - 0.1828 1.47
0.1830 - 0.4567 1.48
0.4579 - 1.4468 1.51
1.4557 - 112.4561 1.31
Urinary Equol (ng/mL) OR
0.0001 - 0.0288 1.00 (Ref)
0.0289 - 0.0560 1.12
0.0560 - 0.0964 1.15
0.0967 - 0.1829 1.11






















for equol, with an increase of 26%. An increased for breast cancer in postmenopausal 
women of 51% was found in the third quintile of genistein.  
 As the confidence intervals are wide and contain 1, there is no statistically 
significant difference in breast cancer risk according to levels of urinary daidzein, 
genistein and equol. These results provide no support for the hypothesis that these 
phytoestrogens may be associated with lower cancer risk. Rather, women with the lowest 




















 The covariates which led to a difference equal to or greater than 5% in covariate 
testing were selected for the final model. These covariates were age, race, BMI, total fruit 
and vegetable intake, and serum cotinine. The analysis found no support for the 
hypothesis that increasing levels of urinary daidzein, genistein, and equol decrease the 
risk for breast cancer in postmenopausal women. There is no meaningful difference in the 
risk for breast cancer in postmenopausal women with increasing levels of each 
phytoestrogen, as the odds fall within the wide confidence intervals.   
 This is consistent with previous findings covered in the introduction, which found 
that daidzein, genistein, and equol influence estrogen receptors to promote the 
progression of cancer cells, interfere with the initiation of protein synthesis via initiation 
factors, as well as interact in the estrogen pathway to prevent reactions, such as sulfation, 
from occurring. Though phytoestrogens exhibit antioxidant properties, this protective 
benefit does not significantly reduce the risk of breast cancer. 
Though the data used in NHANES is composed of adults and children from the 
United States, consumption of soy and cancer outcome may still differ by race. For 
example, Asian Americans consume more fruits and vegetables (which contain 
phytochemicals considered to contain anti-cancer agents), fermented foods, and soy than 
Americans from other ethnic backgrounds, and thus their microbiomes, are likely to 
differ from Americans whose diets are low in fruits, vegetables, and soy. Because of this 
possible difference, “The composition of one’s colonic microbiota can influence the 
metabolic fate and biological effects of isoflavones,” (LPI, Soy Isoflavones) meaning that 
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given differences in gut microbial profiles, some Americans may be better at 
metabolizing daidzein to equol. There are specific equol-producing bacteria in the gut, 
such as those from the genera Pediococcus and Lactobacillus, which are effective equol 
producers. (Kwon et al., 2018) 
The equol that ends up in the urine is downstream of daidzein (daidzein is 
converted to O-desmethylangolensin and then to equol). Adults can be classified as equol 
producers. There may have been some subjects who were more effective at producing 
equol from daidzein due to their intestinal bacteria, thus they would have higher urinary 
equol levels than those lacking the bacteria to metabolize daidzein down to equol. 
Similarly, perhaps those who had higher urinary daidzein levels were not effective equol 
producers, thus any daidzein that they ingested would remain as daidzein with no further 
metabolism. Higher urinary genistein levels may have been due to a subject’s lack of 
intestinal bacteria which convert genistein to p-ethyl phenol. 
 There was a largely skewed distribution of urinary phytoestrogens in the data. 
Daidzein and genistein had some frequencies for greater than 20,000ng/mL (there was 
one observation of 22,600ng/mL for urinary daidzein, and one observation of 
20,900ng/mL for urinary genistein). There are some reasonable speculations for this 
skewed distribution. One reason is kidney function. If kidney function was impaired, it 
may have affected the level of phytoestrogens found in one’s urine. Kidney function was 
further explained by the urinary creatinine variable, as low creatinine levels indicate that 
creatinine is not being properly excreted from the blood into the urine. Kidney 
impairment is recognized with urinary creatinine levels greater than 250mg/dL (the 
 
40 
normal range for urinary creatinine in women is 37-250mg/dL). Another plausible 
explanation for the wide range of urinary phytoestrogens is creatinine, which is used to 
account for dilution of phytoestrogens in the urine. Individuals with extreme values of 
urinary phytoestrogens may have biased the results, as they were not excluded. 
Previous research has adjusted phytoestrogens using creatinine to account for 
dilution in the urine. (Steele & Monteiro, 2017) To correct for dilution of phytoestrogens 
in the urine, the process involved normalizing phytoestrogen concentrations by urinary 
creatinine, which is expressed in mg/g. Each individual’s urinary phytoestrogen 
concentration value, in ng/mL, was divided by the corresponding urinary creatinine 
value, expressed in mg/dL. In this analysis, phytoestrogens were adjusted for urinary 
creatinine. This was also to correct for the very skewed distribution in urinary 
phytoestrogens observed in this subset of data.  
Prior research finds that there is an association between processed foods and 
urinary phytoestrogens, and subjects may under-report how much they consume in 
artificial sweeteners, a substance which causes dilution of phytoestrogens in the urine. 
Steele, 2017 adjusted to account for urinary dilution using creatinine, “In order to correct 
for urine dilution, urinary phytoestrogen concentrations were normalized by urinary 
creatinine (expressed in μg/g creatinine). This was done by dividing each individual’s 
phytoestrogen concentration value (expressed in ng/mL) by the corresponding urinary 
creatinine value (expressed in mg/dL).” (Steele & Monteiro, 2017) 
A potential confounder of this study was the racial breakdown. Of the subjects 
utilized, there was the highest number of Non-Hispanic Whites, and there was no specific 
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categorical designation for Asian-Americans, a population among which there might 
have been even greater variation in urinary phytoestrogen levels. It is uncertain how 
many subjects were Asian-American, but it is assumed that they had been accounted for 
in the category “Other Race – Including Multi Racial.”  
 To conclude, there is no significant decrease in the risk for breast cancer in 
postmenopausal women in association with phytoestrogen intake. Though daidzein, 
genistein, and equol exhibit antioxidant effects, scavenging the reactive oxygen species 
which cause an alteration in redox balance, which ultimately contributes to the DNA 
damage that leads to cancer, these effects were not found to offer any beneficial effect. 
Postmenopausal women with the lowest daidzein and genistein levels had the lowest 
prevalence of breast cancer. There was no association between equol and the prevalence 









Response elements involved in the crosstalk between GPR30, EGFR, ER, ER, 
and MAPK:  Estrogen impacts its receptors, alpha and beta, which then activate estrogen 
response elements. Estrogen response sequences are small DNA segments which are in 
the promoter region of genes. An estrogen-receptor complex can bind to an estrogen 
response element to control transcription. Epidermal growth factor receptors are also 
responsive to estrogen. The epidermal growth factor receptors are connected to the 
MAPK pathway, which activate serum response elements, which are transcription factor 
proteins. GPR30 is another receptor that responds to estrogen, which via the signalling 
cascade and cAMP, influences the cAMP response element. (Aquino et al., 2013) The 
cAMP response element is a response element for the protein CREB, which is also a 
transcription factor.  
 Proteins in the Receptors tyrosine kinase pathway: RAS, RAF, MEK, and ERK,  
are chains of proteins in cells that cascade to signal from the cell’s surface to 
transcription factors within the cell which regulate gene expression. (Chang et al., 2003) 
RTKs are responsive to growth factors which bind to the RTK receptor and activate 
kinases, such as Protein kinase B (AKT), which activate other protein complexes, such as 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B), IB kinase (one 
of the IKKs), and the gene mouse double minute 2 homolog (Mdm2), which encodes an 
E3 ubiquitin ligase that promotes tumorigenesis by causing the degradation of tumor-
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